Latest Middle East News

Memphasys Limited is intensifying its commercial push for Felix, an innovative automated sperm separation system for IVF, backed by a landmark Middle East partnership and a fresh capital raise to scale manufacturing and sales.

Premier Investments reported a 31.1% rise in net profit after tax for FY25, driven by strong growth in its continuing operations after divesting its Apparel Brands to Myer. The company is now concentrating on expanding its high-margin Peter Alexander and Smiggle brands.

Clover Corporation Limited has reported a robust financial year ending July 2025, with revenue climbing 38% and net profit soaring to $7 million. The company also announced a higher fully franked final dividend, reflecting its strengthened financial position.

X2M Connect has secured a significant contract to digitise water meters for 6,750 Seoul households, marking a key step in the city's ambitious A$240 million smart metering initiative.

McLaren Minerals advances its McLaren titanium project with 95% engineering complete and a strong market report confirming demand for its high-quality sulfate ilmenite amid a looming titanium dioxide supply deficit.

Memphasys has upgraded its contract with ITL to A$390,000 and expanded its territory to include Turkey, marking its first contracted revenues in the EU ahead of expected CE Mark approval.

Alligator Energy strengthens its executive team with key appointments as it shifts from exploration to uranium production, closing its Brisbane office and centralising operations in Adelaide.

EPX Limited has landed a significant seven-year contract worth over A$5 million to deploy its EDGE technology across 10 healthcare facilities in the UAE, aiming to boost energy efficiency and sustainability.

Memphasys has inked a five-year exclusive distribution agreement with Middle East leader ITL, unlocking a $325,000 initial order for its Felix™ fertility system upon CE Mark approval. This deal opens access to 15 countries and over 350 IVF clinics, setting the stage for rapid regional adoption.

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

SunRice reported steady FY25 financials with improved profitability despite revenue pressure, while advancing its 2030 Growth Strategy amid industry headwinds and leadership transition.

Cambium Bio has struck a licensing deal with Keke Medtech to commercialise its fibrin biologic in dental applications, unlocking new markets and non-dilutive funding.